th_dXz3G7YV1x9pRpbaq5WX4jegFoLz3bcvuxAdp3ff9jpUtpEjU of Aeternity

SpendTx
block_hash	mh_nqHF7q6tohcJQtVCG9G553YAqsaEeAwuwJsAYo4Sjs1uuhHYf
block_height	256520 879555 blocks confirmed
encoded_tx	tx_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
hash	th_dXz3G7YV1x9pRpbaq5WX4jegFoLz3bcvuxAdp3ff9jpUtpEjU
signatures	sg_G8uDLUpQFcDCQWzkj96cbLe2mbMnvDXsUyeLydXsxmyEn4BQW2Q39K2rey1MhUjtnextSy4tgLpaTmMbwu6wgYNFaN9fk
Tx
	amount	0.1 AE(100000000000000000 ættos )
	fee	0.000055920000000000 AE(55920000000000 ættos )
	nonce	15
	payload	ba_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 (Decoded: {"WeTrue":"0.6.0","content_type":"main","wet_content":"Sorrento soars on positive news from COVID-19 antibody program.\n\nShares in San Diego, USA-based Sorrento Therapeutics (Nasdaq: SRNE) jumped over 200% on Friday, after the firm announced positive data from its COVID-19 antibody program.\n\nThe firm’s candidate, STI-1499, is intended to form part of an antibody cocktail dubbed COVI-SHIELD, which can prevent infection and can remain effective even if virus mutations render a single antibody therapy less effective over time.\n\nThe candidate is also expected to be developed as a stand-alone therapy, COVI-GUARD, due to the high potency it has exhibited in experiments to date.\n\nSTI-1499 demonstrated 100% inhibition of SARS-CoV-2 virus infection in an experiment at a very low antibody concentration.\n\nSorrento has been screening billions of antibodies in its proprietary G-MAB fully human antibody library, and has so far identified hundreds of candidates that bind the S1 subunit of the SARS-CoV-2 Spike protein.\n\nThe firm’s existing cGMP antibody manufacturing facility in San Diego is expected to be able to produce up to two hundred thousand doses per month and the company intends to produce a million doses at risk while seeking Food and Drug Administration approval for any STI-1499 product candidate.\n\nAnticipating high demand, Sorrento is seeking potential government support and pharmaceutical partners to further scale up STI-1499 manufacturing capacity, with a goal of potentially providing tens of millions of doses in a short period of time.\n\nChief executive Henry Ji said: \"Our STI-1499 antibody shows exceptional therapeutic potential and could potentially save lives following receipt of necessary regulatory approvals.”\n\n“We at Sorrento are working day and night to complete the steps necessary to get this product candidate approved and available to the waiting public,\" he added.\n\n ","img_list":""})
	recipient_id	ak_dMyzpooJ4oGnBVX35SCvHspJrq55HAAupCwPQTDZmRDT5SSSW
	sender_id	ak_2u9k4ZqbgRFLEYSU9Zjk5JLfnbvURt9MUsqNbmfcLBqjn1DnN5
	type	SpendTx
version	1

th_dXz3G7YV1x9pRpbaq5WX4jegFoLz3bcvuxAdp3ff9jpUtpEjU details

SpendTx